Imaging and biopsy practices in active surveillance for low-risk prostate cancer
Christopher P. Evans, MD, and J. Brantley Thrasher, MD, conclude an in-depth discussion on active surveillance in men with low-risk prostate cancer.
In the second installment of J. Brantley Thrasher, MD’s interview with Christopher P. Evans, MD, regarding active surveillance for low-risk prostate cancer, Evans discusses his imaging and biopsy regimens, how he handles PI-RADS 3 lesions, and more. Evans is professor and chair of the Department of Urologic Surgery at the University of California, Davis, School of Medicine. Thrasher is executive director of the American Board of Urology, Charlottesville, Virginia.
More videos:
Key steps in pursuing a strategy of active surveillance for very low-risk prostate cancer
What is the learning curve for HIFU for prostate cancer?
App facilitates assess of urologic chronic pelvic pain syndrome
Olaparib monotherapy shows benefit in HRR+ biochemically recurrent prostate cancer
August 22nd 2024“This study is a breakthrough because it is the first trial to show that a non-hormonal drug can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations—one of the most aggressive subtypes of this disease,” says Emmanuel S. Antonarakis, MD.
